Guardant Health (GH) has an "underappreciated" catalyst path as the company's colorectal cancer screening tool has a "greater commercial opportunity" than previously expected, UBS said in a note emailed Friday.
The firm said it was more constructive on genomics application companies versus genomics technology companies in 2025 and that Guardant was its top pick within the group.
UBS said that a survey of physicians indicated that blood-based colorectal cancer screening tools could amount to around 10% of market share in the next one to two years, more than twice the consensus forecasts. This could be a catalyst for Guardant's Shield colorectal cancer screening tool, alongside pricing upside and medical society guidelines, according to UBS.
UBS also struck a positive tone on Natera (NTRA) which it said should continue to ramp volumes for its cancer screening tool Signatera, as well as a "positive growth trajectory" for Veracyte (VCYT).
Price: 36.78, Change: +0.19, Percent Change: +0.52
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。